Drug intelligence / Profile preview

suxamethonium iodide

Development stage
Unknown
Lead developer
Farmstandart-Biolik
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Dityline-Biolik is a brand of suxamethonium iodide (succinylcholine iodide), a short-acting depolarizing neuromuscular blocker. It is developed and manufactured by Farmstandart-Biolik in Ukraine. Suxamethonium iodide acts as an agonist at the muscle-type nicotinic acetylcholine receptors at the neuromuscular junction, causing prolonged depolarization of the motor endplate. This leads to transient muscle fasciculations followed by flaccid skeletal muscle paralysis. It is approved for use as an adjunct to general anesthesia to facilitate endotracheal intubation, provide skeletal muscle relaxation during surgical procedures, and manage convulsions associated with tetanus.

Brand names
AscuronCelocurinCelocurineDitylinDitylin-BiolekDitylin-BiolikDitylin-DarnitsaDityline-Biolik
Other names
diacetylcholine diiodidediacetylcholine iodideditilin iodidesuccinyl choline iodidesuccinylcholine diiodidesuccinylcholine iodidesuccinyldicholine diiodidesuccinyldicholine iodide
02

Targets

mAChR (Muscarinic acetylcholine receptors)ButyrylcholinesteraseMuscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on suxamethonium iodide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on suxamethonium iodide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call